Original Article

Comparative Diagnostic Performance of Flow Cytometry, Aspiration, and Biopsy with Immunohistochemistry in Plasma Cell Neoplasms

Abstract

Background: Plasma cell neoplasms (PCNs) are a heterogeneous group of hematologic malignancies that require accurate and timely diagnosis for effective management. Despite the availability of multiple diagnostic tools, challenges remain due to clinical and morphological variability. This study aimed to compare the diagnostic performance of three key modalities, including flow cytometry (FCM), bone marrow aspiration (BMA), and bone marrow biopsy with immunohistochemistry (BMB+IHC) in patients with plasma cell neoplasms.

Materials and Methods: A cross-sectional study was conducted on 52 patients with confirmed PCNs. Diagnostic outcomes from FCM, BMA, and BMB+IHC were evaluated and compared. Sensitivity, specificity, predictive values, and inter-method agreement were calculated using SPSS version 27.

Results: BMB+IHC achieved the highest diagnostic yield (100%), followed by BMA (55.8%), while FCM demonstrated the lowest diagnostic rate (32.7%). Flow cytometry showed excellent specificity and a positive predictive value of 100%, but limited sensitivity (32.7–58.6%), resulting in a high rate of false negatives. BMA frequently underestimated plasma cell burden due to sampling variability and hemodilution. Collectively, integration of all three methods provided complementary diagnostic value, reducing the risk of misclassification.

Conclusion: Bone marrow biopsy with immunohistochemistry remains the gold standard for diagnosing PCNs. However, combining it with aspiration and flow cytometry offers a more comprehensive diagnostic framework, improving accuracy, minimizing false negatives, and supporting optimal patient management.

 

1. Kaseb H, Durer C, Fazal S, Babiker HM. Plasma cell cancer. 2018.
2. https://www.cancer.gov/types/myeloma
3. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2024;99(9):1802-24.
4. Bergstrom DJ, Kotb R, Louzada ML, et al. Consensus guidelines on the diagnosis of multiple myeloma and related disorders: recommendations of the myeloma Canada research network consensus guideline consortium. Clin Lymphoma Myeloma Leuk. 2020;20(7):e352-e67.
5. Mei L, Shen H, Yu Y, et al. High-throughput and high-accuracy diagnosis of multiple myeloma with multi-object detection. Biomed Opt Express. 2022;13(12):6631-44.
6. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086-107.
7. Yao W, Yang H, You H, et al. The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients. Front Oncol. 2023;13:1266868.
8. Jelinek T, Bezdekova R, Zihala D, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma. J Clin Oncol. 2023;41(7):1383-92.
9. Wei A, Juneja S. Bone marrow immunohistology of plasma cell neoplasms. J Clin Pathol. 2003;56(6):406-11.
10. Gantana EJ, Musekwa E, Chapanduka ZC. Advances in estimating plasma cells in bone marrow: A comprehensive method review. Afr J Lab Med. 2024;13(1):2381.
11. Jelínek T, Bezdekova R, Zatopkova M, et al. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 2017;7(10):e617.
12. Behdad A, Ross CW, Jacques J, et al. Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent m-protein studies in serum and urine. Am J Clin Pathol. 2014;142(3):398-410.
13. Fend F, Dogan A, Cook JR. Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch. 2023;482(1):163-77.
14. Alani A, Choudhuri J, Malonis RJ, et al. Plasma Cell Neoplasms with Unusual Anatomic Locations, Morphology, Phenotype, and Review of Literature: A Case Series. J Clin Transl Pathol. 2023;3(3):138-45.
15. Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192.
16. Prabhakaran N, Scott AW, Esebua M. Utility of Fine Needle Aspiration for Diagnosis of Plasmacytoma. J Med Cases. 2019;10(2):37-40.
17. Wang HW, Lin P. Flow cytometric immunophenotypic analysis in the diagnosis and prognostication of plasma cell neoplasms. Cytometry B Clin Cytom. 2019;96(5):338-50.
18. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-8.
19. Gao Q, Chen X, Cherian S, et al. Mature B‐and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy. Cytometry B Clin Cytom. 2023;104(3):224-42.
20. Lee N, Moon S, Lee J, et al. Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. Blood Cancer J. 2017;7(2):e530.
21. Monteiro C, Campregher P, Pasqualin D, et al. Comparison of plasma cell bone marrow counts by different methods in patients diagnosed with plasma cell disorders. Hematol Transfus Cell Ther. 2024;46 Suppl 6(Suppl 6):S202-S207.
22. Gantana EJ, Musekwa E, Chapanduka ZC. Advances in estimating plasma cells in bone marrow: A comprehensive method review. Afr J Lab Med. 2024;13(1):2381.
23. Sidiqi MH, Aljama M, Kumar SK, et al. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? Blood Cancer J. 2020;10(5):52.
24. Gjelberg HK, Helgeland L, Tsykunova G, et al. Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter! Expert Rev Hematol. 2024;17(9):543-546.
25. Stifter S, Babarović E, Valković T, et al. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma. Diagn Pathol. 2010;5:30.
26. Jain G, Das N, Gajendra S, et al. Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders. Int J Lab Hematol. 2022;44(5):837-845.
27. Terpstra WE 1 , Lokhorst HM, Blomjous F, et al. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol. 1992;82(1):46-49.
28. Paiva B, Vidriales MB, Mateo G, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphologic assessment in myeloma patients. Haematologica. 2009;94(11):1599-602.
29. Rawstron AC, Paiva B, Stetler-Stevenson M, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: consensus recommendations from the European Myeloma Network. Haematologica. 2015;100(3):e146-e149.
Files
IssueVol 19 No 4 (2025) QRcode
SectionOriginal Article(s)
Keywords
Plasma cell neoplasms; Flow cytometry; Bone marrow aspiration; Immunohistochemistry; Diagnostic performance
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Moazedi A, Salarvand S, Salehi Z, Zangooie A, Sahebi L, Abdollahi A, Nili F, Ameli F. Comparative Diagnostic Performance of Flow Cytometry, Aspiration, and Biopsy with Immunohistochemistry in Plasma Cell Neoplasms. Int J Hematol Oncol Stem Cell Res. 2025;19(4):354-364.